ALTSTATION.IO

AbbVie Inc. (ABBV) Stock Analysis

By Nova Skye | AltStation.io | Updated October 03, 2026

Price

$261.56

Change

+0.63%

Market Cap

$462.21B

Avg Volume

4.9M

Company Overview

AbbVie Inc. is a biopharmaceutical giant based in North Chicago, Illinois, operating within the healthcare sector as a general drug manufacturer. The company develops and sells prescription therapies to hospitals, pharmacies, and physicians worldwide. Their core product catalog includes immunology drugs like Skyrizi and Rinvoq, cancer treatments such as Venclexta and Imbruvica, neuroscience therapies like Vraylar, and widely recognized aesthetic brands including Botox Cosmetic and Juvederm. They also sell specialized treatments for eye care, chronic hepatitis C, and gastrointestinal conditions.

AbbVie holds a dominant market leader position in immunology and aesthetics, backed by deep commercial distribution and strong patent moats. Its biggest advantage is the rapid scaling of newer immunology blockbusters Skyrizi and Rinvoq, which brought in 8.03 billion dollars in combined sales in the second quarter of 2026 alone. Despite this strength, AbbVie faces stiff competition from Johnson and Johnson’s Tremfya in immunology, BeiGene’s Brukinsa in blood cancer, and Pfizer’s Nurtec in migraine care. The company’s clearest vulnerability has been generic copycats, which drove legacy blockbuster Humira down 35.9 percent year-over-year to 756 million dollars in quarterly revenue.

Right now, AbbVie is executing a clean post-patent pivot and accelerating into its next growth phase. Combined annual sales for Skyrizi and Rinvoq are on track to surpass 31 billion dollars in 2026, more than absorbing the hit from Humira’s loss of exclusivity. At the same time, high-margin pillars continue to hit new milestones, with Botox Therapeutic crossing 1 billion dollars in quarterly revenue earlier this year. AbbVie handled what could have been a devastating patent cliff cleanly, establishing a diversified portfolio that gives it solid footing for the foreseeable future.

Key Financials

Market Cap

$462.21B

Revenue

$64.39B

EBITDA

$30.76B

Gross Margin

72.8%

Profit Margin

9.8%

Revenue Growth

10.2%

Total Cash

$6.57B

Total Debt

$70.88B

Free Cash Flow

$16.87B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

74.52

Forward P/E

16.09

Beta

0.28

52-Week High

$269.39

52-Week Low

$190.75

EPS

$3.51

50-Day Avg

$257.72

200-Day Avg

$231.34

Price/Book

-77.87

Technical Analysis

ABBV trades at $261.56, 92% of the way from its $189.40 52-week low to its $269.39 high. The stock is 2.44% below that high and 38.76% above the low, confirming a strong 52-week trend. Price is 0.66% above the 20-day moving average of $261.09. Momentum is mixed, with a 0.58% decline over five trading days but a 1.00% gain over 20 trading days. Near-term support sits at $248.78, while $266.28 is the resistance level to beat.

Recent News and Developments

FDA approves AbbVie’s JUVMO for Parkinson’s disease

The FDA approved once-daily JUVMO as the first selective D1/D5 receptor agonist for adults with Parkinson’s disease. In the TEMPO-3 trial, JUVMO plus levodopa increased daily “on” time without troublesome dyskinesia by 1.7 hours versus 0.6 hours for placebo plus levodopa; AbbVie expects a U.S. launch in October 2026. Source: AbbVie

ABBV-295 delivers up to 9.8% weight loss in Phase 1

AbbVie’s long-acting amylin analog produced mean weight reductions of 7.8% to 9.8% with weekly dosing, 9.7% with every-other-week dosing and 7.9% with monthly dosing after 12 to 13 weeks, versus roughly 0.3% for placebo. The 11-to-12-day half-life supports less-frequent dosing, but the 60-person study was small and 88% of participants were male. Source: AbbVie

Zumilokibart clears Phase 2 endpoint in atopic dermatitis

All three zumilokibart regimens produced significantly higher EASI-75 response rates than placebo at week 16 in a 346-patient study. AbbVie selected the mid-dose regimen for Phase 3, advancing another potential immunology growth asset. Source: AbbVie

Market Sentiment and Analyst Recommendations

Bull Case

Revenue is $64.39 billion and is growing 10.2%, giving AbbVie real operating momentum behind the stock’s advance. The FDA approval of JUVMO adds a new Parkinson’s disease product, with a U.S. launch expected in October 2026. JUVMO increased daily “on” time without troublesome dyskinesia by 1.7 hours, compared with 0.6 hours for placebo, in the TEMPO-3 trial. ABBV-295 produced mean weight reductions ranging from 7.8% to 9.8% with weekly dosing, while its 11-to-12-day half-life supports less-frequent dosing. Zumilokibart also cleared its Phase 2 endpoint across all three regimens, and AbbVie selected the mid-dose regimen for Phase 3. The analyst consensus is buy across 28 analysts, with a $278.86 target above the current $261.56 price.

Bear Case

The P/E ratio of 74.52 is the biggest problem with the stock because investors are already paying heavily for future growth. ABBV is also trading just 2.44% below its 52-week high, leaving less room for disappointment. Total debt is $70.88 billion against $6.57 billion in cash, creating a sizable balance-sheet burden. The analyst target range stretches from $200.00 to $328.00, showing that professional expectations are far from settled. ABBV-295’s early weight-loss data came from only 60 participants, and 88% were male, so the results are not broad enough to settle the drug’s commercial potential. At this valuation, weaker trial results, a poor JUVMO launch or slower revenue growth could hit the stock hard.

What to Watch

AbbVie will report third-quarter 2026 results before the market opens on October 30, followed by an earnings call at 8 a.m. Central time. Revenue growth is the first metric to track because the current rate is 10.2%. Investors should watch whether the October 2026 JUVMO launch converts the FDA approval into measurable commercial traction. ABBV-295 needs larger studies to confirm the 7.8% to 9.8% weekly-dosing weight reductions seen after 12 to 13 weeks. Zumilokibart’s move into Phase 3 is another key test after all three regimens produced significantly higher EASI-75 response rates than placebo at week 16. On the chart, a move above $266.28 would strengthen the near-term setup, while a break below $248.78 would weaken it.

Analyst Consensus

BUY

Based on 28 analyst opinions

Low Target

$200.00

Mean Target

$278.86

High Target

$328.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

57,000

Earnings & Dividends

Next Earnings

Oct 30, 2026

EPS (Trailing)

$3.51

Dividend Yield

266.0%

Payout Ratio

190.4%

Frequently Asked Questions

Is ABBV a good stock to buy?

The recommendation is buy based on 28 analysts, and revenue growth is 10.2%. The stock also trades near the top of its 52-week range, so the clear takeaway is that the outlook is bullish but the entry price is demanding.

What is ABBV’s price target?

The analyst target is $278.86, with estimates ranging from $200.00 to $328.00. The clear takeaway is that the consensus target is above the current $261.56 price, but the target range is wide.

What is ABBV’s 52-week high and low?

The technical data puts ABBV’s 52-week high at $269.39 and its low at $189.40. The clear takeaway is that the stock, at 92% of the way through that range, is trading much closer to its high.

What are ABBV’s support and resistance levels?

Near-term support is the 30-day low of $248.78, while near-term resistance is the 30-day high of $266.28. The clear takeaway is that these are the key levels to monitor for the next directional move.

Is ABBV overvalued?

ABBV trades at a P/E ratio of 74.52 and has a market capitalization of $462.21 billion. The clear takeaway is that the valuation is high despite revenue growth of 10.2%.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 03, 2026.